Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;188(3):695-702.
doi: 10.1007/s10549-021-06182-y. Epub 2021 Mar 26.

Tumor subtypes and survival in male breast cancer

Julieta Leone  1 , Rachel A Freedman  2   3 , Nancy U Lin  2   3 , Sara M Tolaney  2   3 , Carlos T Vallejo  1 , Bernardo A Leone  1 , Eric P Winer  2   3 , José Pablo Leone  4   5
Affiliations

Tumor subtypes and survival in male breast cancer

Julieta Leone et al. Breast Cancer Res Treat. 2021 Aug.

Abstract

Purpose: Male breast cancer is an uncommon disease, and population-based information regarding prognostic factors is limited. Most cases are hormone receptor (HR) positive; however, the association of tumor subtype with overall survival (OS) and breast cancer-specific survival (BCSS) is unclear.

Methods: Using SEER data, we identified men with invasive breast cancer between 2010 and 2017 with known HR and HER2 status. We examined tumor subtypes by patient characteristics and performed multivariate Cox proportional hazards analyses to determine the associations of each variable with OS and BCSS.

Results: We included 2389 men with a median follow-up of 43 months (IQR 19-68). Median age was 66 years. Tumor subtype distribution was 84.1% HR+/HER2-, 12.7% HR+/HER2+ , 0.8% HR-/HER2+, and 2.3% triple-negative (TN). In univariate analysis, OS at 5 years was 76.5% for HR+/HER2-, 65.1% for HR+/HER2+ , 84.2% for HR-/HER2+, and 48.1% for TN (p < 0.0001). Of all subtypes, TN had the worst BCSS (p < 0.0001). Stage, tumor subtype and race were significantly associated with OS and BCSS in multivariate analysis. Adjusted Cox hazard ratios for OS by tumor subtype with HR+/HER2- as reference were 1.55 for HR+/HER2+ (p = 0.001), 1.1 for HR-/HER2+ (p = 0.888), and 3.59 for TN (p < 0.001).

Conclusion: We observed significant differences in survival outcomes by tumor subtype. Poor outcomes among men with HER2+ and TN disease suggest possible under-treatment, aggressive tumor biology, and/or more advanced disease at presentation. Studies to better understand the inferior survival for men with these subtypes are warranted and will likely require international collaboration.

Keywords: HER2; Hormone receptor; Male breast cancer; Outcomes; Survival; Tumor subtype.

PubMed Disclaimer

References

    1. Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70. https://doi.org/10.1038/nature11412 - DOI
    1. Network NCC (2020) Breast Cancer (Version 6.2020). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf . Accessed November 19 2020
    1. Giordano SH (2018) Breast Cancer in Men. N Engl J Med 379(14):1385–1386. https://doi.org/10.1056/NEJMc1809194 - DOI - PubMed
    1. Leone J, Zwenger AO, Leone BA, Vallejo CT, Leone JP (2019) Overall Survival of Men and Women With Breast Cancer According to Tumor Subtype: A Population-based Study. Am J Clin Oncol 42(2):215–220. https://doi.org/10.1097/COC.0000000000000497 - DOI - PubMed
    1. Leone JP, Freedman RA, Hassett MJ, Leone J, Tolaney SM, Vallejo CT, Leone BA, Winer EP, Lin NU (2020) Efficacy of neoadjuvant chemotherapy (NAC) in male breast cancer (MaBC) compared with female breast cancer (FBC): A National Cancer Database (NCDB) study. J Clin Oncol 38:587–587. https://doi.org/10.1200/JCO.2020.38.15_suppl.587 - DOI

LinkOut - more resources